NCT01963052View on ClinicalTrials.gov

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

November 14, 2013

Primary Completion Date

July 8, 2019

Study Completion Date

July 8, 2019

Conditions
Metastatic Urothelial Cancer
Interventions
DRUG

AGS15E

intravenous (IV) infusion

Trial Locations (11)

14263

Site US00009, Buffalo

15232

Site US00011, Pittsburgh

35294

Site US00006, Birmingham

37212

Site US00010, Nashville

48201

Site US00001, Detroit

63110

Site US00003, St Louis

98109

Site US00008, Seattle

06510

Site US00002, New Haven

V5Z 1H5

Site CA00004, Vancouver

L8V 5C2

Site CA00007, Hamilton

M4N 3M5

Site CA00005, Toronto

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT01963052 - ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter